Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanfei Baidu granules for asymptomatic and mild COVID-19
ChiCTR2200059818Phase 4Not yet recruiting
- Sponsor
- Tianjin University of Traditional Chinese Medicine
- Start
- Nov 2022
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing Xuanfei Baidu granules with Placebo control (2 arms). Primary endpoints: Progression to moderate or severe COVID-19, Time to nucleic acid negativity and 2 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Xuanfei Baidu
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200059818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059818.